The Next Wave Of US Humira Biosimilars

Generics Bulletin Explains The Coming Adalimumab Competitors

Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.

Black running track with white markings for positions 1 to 8
Eight further FDA-approved Humira biosimilars are set to launch • Source: Shutterstock

Anyone with even a passing interest in the global off-patent industry will likely be aware of the significance of 2023 for the US biosimilars market.

FDA-approved adalimumab biosimilars

Amgen’s Amjevita (adalimumab-atto)

Biocon’s Hulio (adalimumab-fkjp)

Boehringer Ingelheim’s Cyltezo (adalimumab-adbm)

Celltrion’s Yuflyma (adalimumab-aaty)

Coherus’s Yusimry (adalimumab-aqvh)

Fresenius Kabi’s Idacio (adalimumab-aacf)

Pfizer’s Abrilada (adalimumab-afzb)

Samsung Bioepis/Organon’s Hadlima (adalimumab-bwwd)

Sandoz’s Hyrimoz (adalimumab-adaz)

Humira – for a long time the world’s top-selling drug, and still one of the biggest brands in the business...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.